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Abstract
The peripheral nervous system (PNS), including peripheral nerves and dorsal root ganglion (DRG), is involved in
numerous neurological disorders, such as peripheral neuropathies (diabetic neuropathy, chronic pain, etc.) and
demyelination diseases (multiple sclerosis, congenital muscular dystrophy, Charcot-Marie-Tooth disease, etc.).
Effective clinical interventions for those diseases are very limited. Gene therapy represents a novel therapeutic
strategy for the PNS diseases, especially with simply and minimally invasive delivery methods. Previously, we
have shown that adeno-associated virus type 8 (AAV8) can efficiently transduce muscles body wide by a simple
intraperitoneal injection in neonatal mice. In this study, we investigated the capacity of AAV8 in transducing PNS
in neonatal mice by intraperitoneal injection and also in adult mice by intramuscular injection. Efficient and long-
term gene transfer was found in the white matter of the spinal cord, DRG neurons, and peripheral nerves in both
groups, treated either as neonates or as adults, particularly neonates. In the adult mice injected with AAV8 in
tibialis anterior and gastrocnemius muscles in one of the hind legs, more neurons were transduced in the lower
part of the spinal cord than in the upper part; the DRG neurons were transduced more on the vector-injected side
than in the contralateral uninjected side. Few cells in the gray matter of the spinal cord were transduced regardless
of the delivery methods and age of the mice. These results support the mechanism of vector retrograde transport
and suggest that AAV8 crosses blood–nerve barrier poorly. Our finding should have important implications in
gene therapy for peripheral neurological disorders.
Introduction
Peripheral nervous system (PNS) consists of nerves andneurons that are located outside the central nervous sys-
tem (CNS) or extended outside the CNS from the brain and
spinal cord. PNS becomes involved in neuropathies that affect
nerve cells reside either in peripheral ganglia or in the brain or
spinal cord with axons extending into peripheral nerves.
Many inherited and acquired neurological disorders affect
PNS rather than CNS, such as peripheral neuropathy (e.g.,
diabetic neuropathy and chronic pain) as well as demyelin-
ation diseases (e.g., multiple sclerosis and laminin-alpha2-
deficient congenital muscular dystrophy). Fischer et al.
showed that degeneration of neuromuscular junctions oc-
curred before the loss of motor neurons in amyotrophic lateral
sclerosis (ALS) animal models (SOD1 mice) and patients, in-
dicating that ALS can be considered a distal axonopathy
(Fischer et al., 2004). In congenital muscular dystrophy, de-
myelinating peripheral neuropathy is a significant problem
for laminin a2 chain-null mice (Nakagawa et al., 2001; Gawlik
et al., 2006) and MDC1A patient (Cook et al., 1992). The major
pathological process of peripheral neuropathy includes de-
myelination and axonal degeneration, producing symptoms
such as pain, burning, pruitis (itchiness), paresthesias (tin-
gling), numbness, and weakness, eventually leading to pa-
ralysis. These disorders affect 15–20 million of Americans, and
there are very few and limited options for the treatment
(Federici and Boulis, 2007). It is urgent to develop an efficient
method to deliver therapeutic genes to the PNS to achieve
therapeutic efficacy for these disabling diseases (Glorioso et al.,
1995; Glorioso and Fink, 2002, 2009).
It has been reported that adeno-associated virus (AAV)
vector can efficiently transduce dorsal root ganglion (DRG)
neurons, which are sensory neuron cells situated outside of
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spinal column. However, it needs a microneurosurgical tech-
nique to deliver AAV vector to the DRG (Glatzel et al., 2000).
Foust et al. reported that AAV could transduce nerve fibers in
the dorsal horn and columns, indicating DRG transduction,
when AAV serotype8 vector was systemically delivered into
neonatal mice (Foust et al., 2008). In this report, we have in-
dependently studied the ability of AAV8 vector to transduce
DRG, peripheral nerve roots, and CNS by intraperitoneal (i.p.)
injection in neonatal mice. In addition, to find more direct
evidence that AAV8 vector can enter into spinal cord and PNS
via retrograde transport, we also performed direct intramus-
cular (i.m.) injection of AAV8 vector in adult mice. Our results
support the mechanism of retrograde transport, and also
provide insight for gene therapy application for dyemyelina-
tion diseases, chronic pain, and lower motor neuron diseases.
Materials and Methods
AAV vector production
The recombinant viral vector stocks were produced ac-
cording to the three-plasmid cotransfection method (Xiao
et al., 1998). The viral particles were purified twice through
CsCl density gradient ultracentrifugation using the previ-
ously published protocol (Snyder et al., 1996). The vector
titers of viral particle numbers were determined by the DNA
dot blot method. The titer of AAV8-cytomegalovirus (CMV)-
LacZ vector was 51013 vector genomes=ml, and the titer of
dsAAV8-CMV-green florescent protein (GFP) vector was
21012 vector genomes=ml.
Mice and vector injection
All protocol involving animal experiments were approved
by the University of North Carolina Animal Care and Use
Committee. C57=B10 and Imprinting Control Region (ICR)
mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). The dsAAV-CMV-GFP and AAV-CMV-LacZ
vector were delivered into the neonates (3 days old) of
C57=B10 mice, respectively, by i.p. injection with 100ml per
mouse (dsAAV8-CMV-GFP: 21011 vector genomes=
neonatal mouse; AAV8-CMV-LacZ: 51012 vector genomes=
neonatal mouse). Three-week-old adult ICR mice were in-
jected with AAV-CMV-LacZ to tibialis anterior (TA) and
gastrocnemius (GAS) muscles (2.51012 vector genomes=
muscle). Both genes were driven by CMV promoter.
X-gal and histology staining
For AAV-CMV-LacZ-injected samples, we performed
X-gal staining according to previously described protocol
(Sun et al., 2000). Briefly, the cryo-thin tissue sections of the
slides were fixed in fix solution (37% formaldehyde and 25%
glutaraldehyde in PBS) for 10 min followed by PBS wash.
Then, the slides were put in X-gal staining solution overnight
at 378C to incubate, protected from light. All the consecutive
cryo-sections of the spinal cord and brain were performed
with luxol fast blue=Cresyl Echt Violet staining, and the
sections of peripheral nerves and muscles were subjected to
hematoxylin and eosin staining.
Immunofluorescent staining
For dsAAV-CMV-GFP-injected samples, we carried out im-
munofluorescent staining against GFP protein. To avoid high
staining background, the mice were perfused with PBS and
then 4% paraformaldehyde (under anesthesia) at the time of
sacrifice. The primary antibody against GFP was purchased
from Abcam (Cambridge, MA) (ab290-50). Immunofluores-
cent staining of muscle cryo-thin-sections was performed as
previously described (Xiao et al., 2000; Watchko et al., 2002).
Mouse anti-neuronal nuclei (NeuN) antibody (Chemicon,
Billerica, MA; 1:1000), rabbit anti-neurofilament (NeuF) anti-
body (Chemicon; 1:300), rabbit anti-myelin basic protein (MBP)
antibody (Chemicon; 1:100), mouse anti-beta-galactosidase
antibody (Sigma, St. Louis, MO; 1:100), and rabbit anti-beta-
galactosidase antibody (Molecular Probes, Carlsbad, CA; 1:500)
were used for costaining of peripheral nerves and spinal cord.
Results
Efficient transduction of white matter of spinal
cord, DRG, and peripheral nerves in mice
treated as neonates
Previously, we have revealed that delivering AAV8 vec-
tors to neonatal mice can efficiently transduce whole-body
skeletal and cardiac muscles by a simple i.p. injection (Wang
et al., 2005; Qiao et al., 2008, 2009). To explore the feasibility
of using AAV vector to infect PNS and spinal cord, we ap-
plied the same AAV serotype and similar delivery route in
neonatal mice. We first utilized AAV-CMV-LacZ vector. Two
months after vector injection, the mice were sacrificed. The
whole spinal cord including bone and some adjacent muscles
were cut into three segments (cervical, thoracic, and lumbar)
and snap-frozen. Cryo-thin-sections were subjected to X-gal
staining for LacZ expression and hematoxylin and eosin
staining on the consecutive sections to display the histology.
As shown in Fig. 1A, the majority of LacZ-positive cells were
located in white matter in the spinal cord of AAV-CMV-
LacZ-injected mice. We also observed cells expressing LacZ
in ventral horns of gray matter (black arrows in Fig. 1A and
B), which showed button-like structures in the proximity and
overlapping neurons (Fig. 1B). Notably, there were more
LacZ-positive cells in the lower spinal cord such as lumbar
segment than the higher ones such as cervical segment.
In addition, we noticed that AAV8 vector could efficiently
infect DRG neurons that were positioned outside the spinal
cord (Fig. 2A, white arrow). Across the entire spine, the DRG
neuronal cells were effectively transduced by AAV8 (Fig. 2).
Further, we also noticed that the AAV vector could effi-
ciently transduce peripheral nerve cells. As shown in Fig. 2B,
we observed LacZ-positive cells in nerve roots of AAV-
CMV-LacZ-injected mice. There are several cell types in
nerve roots, including Schwann cells, fibroblast, and mac-
rophages (Yaksh, 1999). It is likely that the AAV8 vector
infected Schwann cells as we previously observed in the
basal lamina of Schwann cells on expression of an extracel-
lular protein, the mini-agrin (Qiao et al., 2005).
We next examined whether utilizing AAV vector carrying
a different reporter gene, such as GFP, would generate the
similar results as AAV-CMV-LacZ vector. Similar to AAV-
CMV-LacZ vector delivery, dsAAV8-CMV-GFP was deliv-
ered into neonatal mice via i.p. injection. The mice were
sacrificed 2 months postinjection. Immunofluorescent stain-
ing against GFP indicated that most of the GFP-positive cells
were located in white matter of spinal cord and DRG (Fig.
3A, white arrow; with greater than 70% positive DRG cells),
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which is consistent with the LacZ study. Besides white
matter of spinal cord and DRG, we also noticed widespread
GFP staining in peripheral nerve fibers (Fig. 3B).
Efficient retrograde transport of AAV8
vector in adult mice
In our neonatal study by systemic AAV8 delivery, it is
possible that the efficient transduction of PNS and spinal
cord could be through vector retrograde transport from the
muscle as well as directly crossing the blood–nerve barrier.
To obtain direct proof that AAV vector can enter into PNS
and spinal cord by retrograde transport, we delivered AAV-
CMV-LacZ vector to 3-week-old young adult mice by i.m.
injection. The vector was injected into TA and GAS muscles
of one leg, leaving the contralateral one as an uninjected
control. The mice were sacrificed at 1, 2, and 3 months post-
injection. Again, the whole spinal cord including bone and
adjacent muscles was isolated, divided into cervical, thoracic,
and lumbar segments and snap-frozen. After cryo-thin sec-
tioning, the slides were subjected to X-gal staining and luxol
fast blue staining, which can clearly differentiate the fiber
tracts (white matter) from neuronal cell bodies (gray matter).
As shown in Fig. 4A, consistent with what we observed in
neonatal mice, most LacZ-positive cells were seen in white
matter in the spinal cord of AAV-CMV-LacZ-injected mice at
1 month after i.m. injection (black arrowheads). In addition,
most LacZ-positive cells were found in lower spine portion,
that is, the lumbar segment. Nevertheless, 2 months postin-
jection, more LacZ-positive cells were detected in the upper
portions such as cervical and thoracic segments besides
the lower ones (Fig. 4A). In addition, we observed several
FIG. 1. Intraperitoneal injection of AAV-CMV-LacZ leads to neonatal spinal cord transduction. (A) LacZ-positive cells in
white matter. About 51012 vector genomes of dsAAV8-CMV-LacZ were delivered on 3-day-old neonatal mice, and the mice
were sacrificed at 2 months of age. Notably, most of the lacZ-positive spots were in white matter (black arrowheads and insets),
and very few LacZ-positive cells were in gray matter (black arrows). Insets show enlarged area. The consecutive sections of
H&E staining were used to display the structure of spinal cord. It was also apparent that there were more LacZ-positive cells in
lower spine, followed by medium spine, and then the upper one. (B) LacZ-positive cells in gray matter. Button-like structures
(black arrow) in gray matter indicate small neuron and axonal communication. AAV, adeno-associated virus; CMV, cyto-
megalovirus; H&E, hematoxylin and eosin. Color images available online at www.liebertonline.com=hum.
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LacZ-positive cells in the brain 3 months after hind leg
i.m. delivery in the adult mice. As shown in Fig. 4B, there were
several LacZ-positive cells located in the white matter of the
dorsal part of the brain stem, most probably in the gracile
fasciculus and cuneate fasciculus. Our results suggest that
AAV8 gene transfer and expression in the spinal cord is likely
through retrograde transport from peripheral nerve axons.
To further define the route through which AAV8 vector
travels to the PNS and CNS from the injection site in the
muscle rather than systemically, we analyzed LacZ gene ex-
pression in different muscle groups and peripheral nerves
including sciatic and peroneal nerves, on both sides of the
body. Our results showed that strong LacZ-positive cells
were found in the vector-injected TA and GAS muscles and,
to a less degree, the other muscle groups on the same hind
leg (Fig. 5, white arrowhead). However, very few and faint
LacZ-positive muscle cells were found in the contralateral
side (data not shown), suggesting that systemic dissemina-
tion of AAV8 is very limited after i.m. injection in the lower
hind leg. The sciatic nerve on the injected side was lacZ
positive (Fig. 5 black arrow), but the contralateral one was
negative (data not shown). Interestingly, LacZ-positive cells
were found in bilateral DRG (Fig. 5, white arrow), bilateral
spinal cord (Fig. 4A), and brain stem (Fig. 4B). This result
demonstrated that the retrograde transport is probably the
mechanism of LacZ transduction to CNS by AAV8 vector via
i.m. injection.
To determine which cell type in spinal cord and PNS is
transduced by AAV8 vector, we performed double immu-
nofluorescent staining with anti-beta-galactosidase (LacZ)
and antibodies specific for neural cell, nerve axon, as well as
Schwann cell markers. As we described earlier, in the spinal
cord, we observed a number of LacZ-positive cells in dorsal
horns of gray matter. To find out whether those AAV-
transduced cells are neurons, we performed costaining
against LacZ antibody and anti-NeuN protein antibody, a
marker confined to almost exclusively neurons (Mullen et al.,
1992; Wolf et al., 1996). Our results indicated colocalization of
LacZ signal and NeuN signal (Fig. 6, white arrow and inset
area), demonstrating transduction of neurons in the spinal
cord by AAV8 vector through retrograde via i.m. delivery in
adult mice. To identify which cell types were transduced by
AAV8 vector in peripheral nerves, we did costaining of LacZ
antibody and one of the major CNS myelin protein marker
synthesized by oligodendrites (central) and Schwann cells
(peripheral) (Morell, 1984)—anti-MBP (Grima et al., 1992), as
well as the axoplasm marker in dendrites and axons—anti-
NeuF (Karlsson et al., 1989). As shown in Fig. 7A, most
LacZ-positive signals colocalized with anti-NeuF staining,
indicating the presence of LacZ in nerve fibers transported
from the neuronal axons. Additionally, some LacZ-positive
cells were also stained positive in MBP, suggesting the
transduction of myelinating Schwann cells in peripheral
nerve by AAV8 vector (Fig. 7B).
Discussion
Gene therapy for peripheral neuropathies invokes thera-
peutic gene delivery to the spinal cord and PNS. In this
study, we found that efficient gene transfer to the spinal
cord and PNS could be achieved by simple gene delivery
methods—thus, injection of AAV8 vectors in neonatal mice
intraperitoneally and in adult mice intramuscularly. While
our data obtained from neonatally injected mice are consis-
tent with a previous report (Foust et al., 2008), data from
adult mice intramuscularly injected with AAV8 vectors
FIG. 2. AAV-CMV-LacZ vector efficiently transduced dorsal root ganglion (DRG) and peripheral nerves in neonatal de-
livered mice. (A) Transduction of DRG cells. White arrows indicate LacZ-positive cells in DRG, which locates outside the
spinal cord, and the consecutive section of H&E staining was utilized to display DRG structure and location. White ar-
rowheads point to the adjacent LacZ-positive muscle cells. (B) Transduction of peripheral nerves by AAV-CMV-LacZ vector.
Color images available online at www.liebertonline.com=hum.
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FIG. 3. Immunofluorescent staining of GFP in spinal cord, peripheral nerves, and DRG demonstrates that those cells could be
efficiently transduced by AAV8-GFP vector in neonates. Similar to AAV8-CMV-LacZ vector, the 21012 vector genomes=ml
dsAAV8-CMV-GFP vector was also delivered into neonatal mice by intraperitoneal injection (21011 vector genomes=neonatal
mouse). Two months after vector delivery, the mice were sacrificed. (A) Transduction of white matter of spinal cord and DRG
by dsAAV-CMV-GFP vector. The same as the results obtained from LacZ staining, most GFP-positive signals (white arrow)
were located in white matter of spinal cord and DRG. The neurons located in DRG transduced by AAV vector are about 70–
80%. The consecutive sections of H&E staining were used to display the structure. (B) Transduction of peripheral nerves by
dsAAV8-CMV-GFP vector. Insets show enlarged area. GFP, green florescent protein.
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provide new evidence supporting retrograde transport of
AAV vectors in the nervous system (Kaspar et al., 2003; Lu
et al., 2003; Xu et al., 2005; Pirozzi et al., 2006; Foust et al.,
2008; Hollis et al., 2008). These findings should have valuable
implications in gene therapy for neurological disorders.
Retrograde transport of AAV vectors from muscle to the
spinal cord was first reported by Kaspar et al. using AAV2
vectors in an ALS mouse model (Kaspar et al., 2003). Sub-
sequently, to find vectors with higher efficiency, more sero-
types of AAV vectors have been explored for retrograde
transport from muscle to nerve (Burger et al., 2004; Xu et al.,
2005; Federici and Boulis, 2007; Foust et al., 2008; Hollis
et al., 2008; Foust et al., 2009). A recent report by Hollis et al.
demonstrated that AAV1 is effective in retrograde transport
(Hollis et al., 2008). Previously, several groups, including our
own (Inagaki et al., 2006), have shown that certain AAVs like
AAV8 and AAV9 exhibit superior capability of widespread
gene transfer to skeletal muscles throughout the body. This
prompted us to investigate AAV8 in this aspect. Gene ex-
pression in PNS and spinal cord via retrograde transport by
AAV8 was not reported until recently in neonatal mice
(Foust et al., 2008). We have done similar studies on AAV8 in
neonatal mice and observed consistent results. Nonetheless,
if AAV8 readily crossed blood-brain barrier (BBB), we should
have seen more neurons expressing LacZ in gray matter than
we observed, but we found only very few positive neurons
throughout different ages and time points. These observa-
tions suggest that AAV8 vector crosses BBB poorly even in
neonatal stage before the closure of the BBB and that AAV8
gene transfer in gray matter is most likely from retrograde
transport through nerve terminals rather than BBB crossing.
In contrast, a recent study revealed that AAV9 is superior in
crossing the BBB and renders efficient gene transfer to the
brain and spinal cord after intravenous vector injection
(Foust et al., 2009). However, AAV9 is much less effective in
retrograde transport from muscle to the nerve than AAV8
(Zheng et al., unpublished observation).
Systemic neonatal vector delivery is only useful for certain
diseases that require early interventions, whereas retrograde
gene transfer to nervous system by i.m. injection in adult is
FIG. 4. Intramuscular injection of AAV-CMV-LacZ leads to spinal cord transduction. (A) LacZ-positive cells in spinal cord
of vector-delivered mice (10). The vector was delivered on 3-week-old adult mice and the mice were sacrificed 1, 2, or 3
months after injection. Obviously, most of the lacZ-positive spots were in white matter (WM; black arrowheads and insets),
and very few LacZ-positive cells were in gray matter (GM; black arrows). Insets show enlarged areas of WM (40). LFB
staining was used on consecutive sections to display the structure of spinal cord. (B) LacZ staining of brain stem in AAV8-
CMV-LacZ-delivered adult mice. The mice were sacrificed 3 months after intramuscular injection. Some LacZ-positive cells
were found in the WM of the dorsal part of the left upper brain stem (inset area), most likely in the gracile fasciculus and
cuneate fasciculus. Inset shows the enlarged area (40). The consecutive section of LFB staining was used to display the
structure of the brain stem. LFB, luxol fast blue. Color images available online at www.liebertonline.com=hum.
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FIG. 5. Transduction of peripheral nerves and DRG by AAV-CMV-LacZ vector via intramuscular delivery in adult mice.
LacZ-positive cells were found in peripheral nerves (black arrows) and DRG (white arrows), which was located outside of
sacrococcygeal spine. LacZ-positive cells were found in skeletal muscles (white arrowheads). H&E staining was used to display
the structure of peripheral nerve and DRG. WM, white matter. Color images available online at www.liebertonline.com=hum.
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more applicable to a broad range of peripheral neurological
and neuromuscular disorders. In the current study, we are
able to demonstrate that AAV8 vector could also efficiently
transduce spinal cord, DRG neurons, as well as peripheral
nerve in adult mice after i.m. injection. We have two im-
portant observations that further support the notion of ret-
rograde transport from nerve endings in the muscle to the
neuron cell bodies, rather than systemically crossing the BBB
by AAV8. First, more nerve cells were transduced in the
proximity to the vector-injected muscles (TA and GAS on the
lower hind leg) than the distal sites, for example, upper
segment of the spinal cord. Second, LacZ-positive muscle
cells are predominantly localized in the vector-injected side
and few positive cells were found in the contralateral side,
indicating that local trafficking other than systemic traffick-
ing is a primary mechanism. As a result, it is not surprising
that the DRG cells were transduced by AAV8 vectors be-
cause the perineurium of DRG has fewer layers of peri-
neurial cells and larger gaps than the peripheral nerves
(Yaksh, 1999), making DRG more accessible to AAV8 parti-
cles (Yaksh, 1999).
The ability of AAV vector to transduce peripheral nerve
roots and white matter of spinal cord indicated that AAV
vector could cross the perineurium and achieve gene transfer
there. Nerve roots include both sensory (dorsal) and motor
(ventral) bundles. We believe AAV8 vector can cross not
only sensory perineurium but also motor perineurium,
though with much lower efficiency in the latter. Previously,
we have shown that AAV1-mini-agrin, encoding an extra-
cellular protein, can be expressed in the basal lamina of
FIG. 6. Transduction of neuronal cells of spinal cord via retrograde transport of AAV-CMV-LacZ vector. Costaining of
anti-beta-galactosidase (LacZ) and anti-neuronal nuclei (NeuN) of lumbar spinal cord showed some colocalization of NeuN-
positive cells with LacZ (white arrows)-positive signal, demonstrating that neurons in the spinal cord were transduced. The
inset is a magnification of an LacZ-positive neuron. Color images available online at www.liebertonline.com=hum.
FIG. 7. Characterization of LacZ-positive cells in peripheral nerves in mice injected intramuscularly. (A) Neuron axon was
transduced by AAV-CMV-LacZ vector. Colocalization of LacZ and neurofilament (nerve fiber marker) indicated that neu-
ronal axons in peripheral nerves were transduced by AAV-CMV-LacZ vector (white arrowheads). The inset is an enlarged
magnification of an LacZ-positive neuronal axon (cross section). (B) Schwann cells were also transduced by AAV-CMV-LacZ
vector via retrograde. Colocalization of LacZ and the myelin basic protein (MBP) indicated that myelinating Schwann cells
were also transduced (white arrows).
‰
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peripheral nerves when the vector was delivered in neonates
(Qiao et al., 2005). Those data are consistent with our current
findings.
Directing gene transfer to neurons has a number of op-
tions: (1) directly injecting the brain and spinal cord to by-
pass the BBB (Alisky and Davidson, 2000); (2) using vectors
that can cross the BBB (Foust et al., 2009); (3) taking advan-
tage of retrograde transport (Eusebio et al., 2003; Kaspar et al.,
2003; Foust et al., 2008). The ability of AAV8 to direct gene
transfer mainly to axons and myelin of peripheral nerve and
white matter of spinal cord makes it a useful tool for de-
myelinating diseases or other disease with demyelinating
process, such as CMD. Although AAV8 vector transduces
lower motor neurons poorly, systemic delivery of AAV
vector encoding secreted protein to spinal cord through DRG
will still be an attractive therapeutic approach for motor
neuron disease such as ALS. DRG is a group of sensory
nerve bodies. In addition to sending sensory information to
the brain via the dorsal columns, the DRG sends projections
to lower motor neuron or interneuron as a part of reflex arc
(Yaksh, 1999). Synapses on lower motor neuron could be an
efficient means to deliver neurotrophic factors to diseased
cells. Our study also indicates that if a therapeutic protein is
intracellular and needs to be delivered to a large portion of
lower motor neurons, such as in the case of spinal muscular
atrophy, alternative delivery route and more efficient vectors
have to be further pursued.
In addition, DRG transduction could have potential ben-
efit in models of chronic pain (Federici and Boulis, 2007;
Storek et al., 2008; Beutler and Reinhardt, 2009). Xu et al. have
achieved strong GFP expression with AAV vector in DRG,
dorsal roots, and peripheral axons (Xu et al., 2003a). They
have also obtained very encouraging therapeutic efficacy in
pain treatment (Xu et al., 2003b). However, they utilized di-
rect DRG injection and sciatic nerve injection, which were
more sophisticated than i.m. injection. Systemic delivery
with AAV serotype 8 described in our study could be a more
convenient alternative route to deliver genes to DRG for
treatment of neuropathic pains and other neuromuscular
diseases.
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